Yin and Yang of PDGF-mediated signaling pathway in the context of HIV infection and drug abuse

Honghong Yao, Crystal Bethel-Brown, Fang Niu, Lu Yang, Fuwang Peng, Shilpa J Buch

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The control and eradication of neurological complications associated with AIDS continues to be an important goal in efforts toward improving the well being of HIV-infected patients. Although combined antiretroviral therapies have contributed significantly to increasing the longevity of patients by suppressing the virus burden in the systemic compartments, the prevalence of HIV-associated neurological disorders continues to be on the rise. This in turn, leads to an impaired quality of life of the infected individuals who continue to suffer from mild to moderate cognitive decline and memory loss. Developing therapeutic interventions that reverse neuronal injury in the context of HIV infection, is thus of paramount importance in the field. Our previous studies have demonstrated that platelet-derived growth factor (PDGF) has a neuroprotective potential against HIV envelope protein gp120 and Tat. Paradoxically, PDGF is also a cerebrovascular permeant with deleterious effects on the blood-brain barrier resulting in increased influx of monocytes in the CNS. Herein, we review the opposing roles of PDGF in the context of HIV-associated neurodegenerative disorder (HAND).

Original languageEnglish (US)
Pages (from-to)161-167
Number of pages7
JournalJournal of Neuroimmune Pharmacology
Volume9
Issue number2
DOIs
StatePublished - Mar 2014

Fingerprint

Yin-Yang
Platelet-Derived Growth Factor
HIV Infections
Substance-Related Disorders
HIV
HIV Envelope Protein gp120
Memory Disorders
Nervous System Diseases
Blood-Brain Barrier
Neurodegenerative Diseases
Monocytes
Acquired Immunodeficiency Syndrome
Quality of Life
Viruses
Wounds and Injuries
Therapeutics

Keywords

  • Drug Abuse
  • HIV
  • PDGF

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Yin and Yang of PDGF-mediated signaling pathway in the context of HIV infection and drug abuse. / Yao, Honghong; Bethel-Brown, Crystal; Niu, Fang; Yang, Lu; Peng, Fuwang; Buch, Shilpa J.

In: Journal of Neuroimmune Pharmacology, Vol. 9, No. 2, 03.2014, p. 161-167.

Research output: Contribution to journalReview article

Yao, Honghong ; Bethel-Brown, Crystal ; Niu, Fang ; Yang, Lu ; Peng, Fuwang ; Buch, Shilpa J. / Yin and Yang of PDGF-mediated signaling pathway in the context of HIV infection and drug abuse. In: Journal of Neuroimmune Pharmacology. 2014 ; Vol. 9, No. 2. pp. 161-167.
@article{06e739e06ff54e16923068872c8ad8d9,
title = "Yin and Yang of PDGF-mediated signaling pathway in the context of HIV infection and drug abuse",
abstract = "The control and eradication of neurological complications associated with AIDS continues to be an important goal in efforts toward improving the well being of HIV-infected patients. Although combined antiretroviral therapies have contributed significantly to increasing the longevity of patients by suppressing the virus burden in the systemic compartments, the prevalence of HIV-associated neurological disorders continues to be on the rise. This in turn, leads to an impaired quality of life of the infected individuals who continue to suffer from mild to moderate cognitive decline and memory loss. Developing therapeutic interventions that reverse neuronal injury in the context of HIV infection, is thus of paramount importance in the field. Our previous studies have demonstrated that platelet-derived growth factor (PDGF) has a neuroprotective potential against HIV envelope protein gp120 and Tat. Paradoxically, PDGF is also a cerebrovascular permeant with deleterious effects on the blood-brain barrier resulting in increased influx of monocytes in the CNS. Herein, we review the opposing roles of PDGF in the context of HIV-associated neurodegenerative disorder (HAND).",
keywords = "Drug Abuse, HIV, PDGF",
author = "Honghong Yao and Crystal Bethel-Brown and Fang Niu and Lu Yang and Fuwang Peng and Buch, {Shilpa J}",
year = "2014",
month = "3",
doi = "10.1007/s11481-013-9481-5",
language = "English (US)",
volume = "9",
pages = "161--167",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Yin and Yang of PDGF-mediated signaling pathway in the context of HIV infection and drug abuse

AU - Yao, Honghong

AU - Bethel-Brown, Crystal

AU - Niu, Fang

AU - Yang, Lu

AU - Peng, Fuwang

AU - Buch, Shilpa J

PY - 2014/3

Y1 - 2014/3

N2 - The control and eradication of neurological complications associated with AIDS continues to be an important goal in efforts toward improving the well being of HIV-infected patients. Although combined antiretroviral therapies have contributed significantly to increasing the longevity of patients by suppressing the virus burden in the systemic compartments, the prevalence of HIV-associated neurological disorders continues to be on the rise. This in turn, leads to an impaired quality of life of the infected individuals who continue to suffer from mild to moderate cognitive decline and memory loss. Developing therapeutic interventions that reverse neuronal injury in the context of HIV infection, is thus of paramount importance in the field. Our previous studies have demonstrated that platelet-derived growth factor (PDGF) has a neuroprotective potential against HIV envelope protein gp120 and Tat. Paradoxically, PDGF is also a cerebrovascular permeant with deleterious effects on the blood-brain barrier resulting in increased influx of monocytes in the CNS. Herein, we review the opposing roles of PDGF in the context of HIV-associated neurodegenerative disorder (HAND).

AB - The control and eradication of neurological complications associated with AIDS continues to be an important goal in efforts toward improving the well being of HIV-infected patients. Although combined antiretroviral therapies have contributed significantly to increasing the longevity of patients by suppressing the virus burden in the systemic compartments, the prevalence of HIV-associated neurological disorders continues to be on the rise. This in turn, leads to an impaired quality of life of the infected individuals who continue to suffer from mild to moderate cognitive decline and memory loss. Developing therapeutic interventions that reverse neuronal injury in the context of HIV infection, is thus of paramount importance in the field. Our previous studies have demonstrated that platelet-derived growth factor (PDGF) has a neuroprotective potential against HIV envelope protein gp120 and Tat. Paradoxically, PDGF is also a cerebrovascular permeant with deleterious effects on the blood-brain barrier resulting in increased influx of monocytes in the CNS. Herein, we review the opposing roles of PDGF in the context of HIV-associated neurodegenerative disorder (HAND).

KW - Drug Abuse

KW - HIV

KW - PDGF

UR - http://www.scopus.com/inward/record.url?scp=84896548674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896548674&partnerID=8YFLogxK

U2 - 10.1007/s11481-013-9481-5

DO - 10.1007/s11481-013-9481-5

M3 - Review article

C2 - 23784143

AN - SCOPUS:84896548674

VL - 9

SP - 161

EP - 167

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 2

ER -